Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Vasculitis 1Urogenital Neoplasms 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Pemphigoid, Benign Mucous Membrane 1Melanoma 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Granulomatous Disease, Chronic 1Cytokine Release Syndrome 1Crohn Disease 1Colitis 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

vedolizumab 1LDP-02 1Infliximab 1Immunoglobulin G 1Disulfides 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colitis × Infliximab × Clear all
NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡